An interventional study of Adaptango Performance Process (APP) program in Parkinson Disease, Mild Cognitive Impairment and Old Age; Dementia, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Emory University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 231st largest by planned enrollment of the 1,256 interventional ones that give a count, is one of 83 that started in 2026, is one of 585 with no phase, reaches primary completion later than 330 of the 384 other live ones, and was the 1,639th registered.
4,576 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, United Kingdom
Ages 40–85
Medical University of South Carolina · Sites in United States
Ages 50–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 749 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,649 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 83 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,256 interventional studies, 78 across the 379 observational. Of the 1,139 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,649 have an industry lead sponsor. The 10 most frequent:
Emory University is the lead sponsor of 1,405 studies on the registry; 223 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 178 (75%) have results posted.
Emory University has 9 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
137 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT05558189Stanford UniversityVibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients | 2026-11-21 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
Add all 137 to your calendar (.ics) → With an account.
Among the 1,649 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to answer the question: How do people with Parkinson's disease, people with Mild Cognitive Impairment, and younger people process difficult topics in conversation? It will also explore themes related to dance, such as community building and justice, as perceived by persons with Parkinson's disease or Mild Cognitive Impairment, and younger individuals before and after the Adaptango performance process.
This is a pilot study designed to assess the impact of the mediator/instructor role between dyads of older and younger adults as they engage in art and dance activities that address challenging topics.
The study aims to evaluate the effects of the Adaptango Performance Process (APP) on creativity, justice, and quality of life among persons with Parkinson's disease (PWP), people living with dementia (PLWD), and young adult participants. Validated measures of creativity, justice, and quality of life will be administered before and after the intervention.
The findings from this pilot phase will be used to inform the design and power calculations of future larger clinical trials intended to more definitively evaluate the effects of the APP program on creativity, engagement with challenging topics of societal importance, and psychosocial health across generations.
Findings from the arts-based method evaluation will also be considered when interpreting and reporting study results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy adults over 18 and less than 31 years
Other: Adaptango Performance Process (APP) program
Adults with Parkinson's disease aged 50 years and over
Other: Adaptango Performance Process (APP) program
Adults with MCI aged 50 years and over
Other: Adaptango Performance Process (APP) program
Participants will take a three-month, biweekly choreographic process, ending in a weekend performance workshop at Emory University. Tango instructors undergo 13 hours of American Council on Exercise-certified training on Adaptango methods, age-specific functional impairments, and fall detection and prevention. Adaptango modifications were made to the frame and several steps of Argentine tango.
Participants' Satisfaction of the intervention (Acceptability)
Satisfaction will be assessed post-intervention only with an Exit Questionnaire balanced for gender and race. Participants will rate (extremely easy/very easy) and their overall satisfaction with the intervention. A higher score indicates better satisfaction.
Time frame: Post-intervention at 8 months
Alternate Uses Task (AUT)
The Alternate Uses Task (AUT) will be used to assess the patient's creativity by asking them to come up with as many alternate uses for an everyday object as possible in two minutes. Results are measured across four subscales: fluency- the number of alternative uses thought of originality - how unusual the uses given are; flexibility - the range of ideas in different categories; and elaboration-the level of detail given to an idea. Higher values in each subscale indicate higher levels of creativity.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
Parkinson's Disease Questionnaire Summary Index (PDQ-39 SI)
The PDQ-39 is a patient-reported, disease-specific questionnaire used to assess health status and quality of life in Parkinson's disease over the preceding month. It consists of 39 items grouped into 8 distinct dimensions: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items), and bodily discomfort (3 items). Each item is scored on a 5-point Likert scale indicating frequency: 0 (never), 1 (occasionally), 2 (sometimes), 3 (often), and 4 (always or cannot do at all). The PDQ-39 Summary Index (PDQ-39 SI) is derived by calculating the mean of the 8 dimension scores. Total index scores range from 0 to 100. Lower scores reflect a better health status/quality of life, while higher scores indicate a greater frequency and severity of health-related difficulties.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
The Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
The Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a comprehensive 50-question clinical tool used to evaluate both motor and non-motor symptoms, severity, and progression of Parkinson's disease. Each item is scored from 0 (normal) to 4 (severe), with higher summed subscale scores indicating greater disability.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
30-second chair stand test
The number of sit-to-stand maneuvers completed in 30 seconds is used to measure leg strength and endurance. A higher score is better.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
Timed Up and Go Simple and Dual tasks (TUG, TUG Cognitive and TUG Manual)
Measures the time it takes to rise from a chair, walk 3 meters, turn around, and return to the chair in the simple condition. In the Cognitive condition, one is required to simultaneously count backward by 3s from a number between 20 and 100; in the Manual condition, one is required to simultaneously pick up a cup of water and carry it while completing the task. A lower score is a better outcome.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
360 turn test (Time)
The time it takes the participants to turn around in a complete circle. Lower times are better.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
360 turn test (steps)
The number of steps the participant takes to turn around in a complete circle. Lower number of steps is better.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
Static Postural Balance Assessment via Tandem Stance Test
Participants are instructed to stand with one foot directly in front of the other, heel-to-toe, with eyes open and arms at their sides or crossed over the chest. The examiner assists the participant into position and begins timing with a stopwatch once the examiner releases their hand support. Timing is recorded in seconds and ceases if the participant moves their feet, reaches for support, opens their eyes (if an eyes-closed variant), or reaches the ceiling threshold
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
Mini-Balance Evaluation Systems Test (Mini-BESTest)
Mini-BESTest (Mini-Balance Evaluation Systems Test) is a validated, performance-based assessment used to evaluate balance, functional mobility, and fall risk. It includes 14 items across four domains, with each item scored from 0 to 2: 2 = Normal: Completes the task safely, quickly, and independently. 1 = Mild impairment: Completes the task with hesitation, slower movement, uneven weight shifts, or use of an assistive device. 0 = Severe impairment/Unable: Requires physical assistance or cannot complete the task safely. Total Score Interpretation (0-28): 27-28: Normal balance; no significant deficits. 22-26: Mild balance impairment; monitoring or preventive exercise may be beneficial. \<22: Significant balance impairment, indicating increased balance dysfunction and fall risk.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
The Dynamic Gait Index (DGI)
DGI is an 8-item clinical assessment used to evaluate gait adaptability and balance during functional walking tasks. Each item is scored on a 4-point scale (0-3): 3 = normal performance; 2 = mild impairment; 1 = moderate impairment; 0 = severe impairment or inability to perform independently. Total scores range from 0 to 24, with higher scores indicating better dynamic balance and mobility. Scores of 22-24 indicate normal balance and safe ambulation; 19-21 indicate mild instability; scores \<19 are associated with increased fall risk in older adults and individuals with neurological conditions.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
Gait speed test
Gait speed testing (Forward/Backwards/Fast): How quickly a person can walk a specific distance forward and Backwards using a stopwatch. Faster speeds (m/s) are better.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
Four-square step test
The Four Square Step Test (FSST) is a quick clinical tool used to measure dynamic balance, agility, and the risk of falls by having a person rapidly step over low obstacles-traditionally four canes arranged in a plus-sign configuration on the floor. Because the Four Square Step Test (FSST) is a timed test, it does not use a point-based scale. Instead, performance is measured solely by the number of seconds it takes to complete the pattern. Normal values for the Four Square Step Test (FSST) generally range from under 10 to 15 seconds for healthy adults. A completion time of under 15 seconds indicates a low risk for falls in older adults, while a time of 15 seconds or longer suggests an increased risk for multiple falls.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
The Multidimensional Scale of Perceived Social Support (MSPSS) Score
The MSPSS has 12 items that assess how social support factors are perceived by individuals. This scale has three subscales to evaluate support by family, friends, and significant others. Respondents rate statements on a scale of 1 (very strongly disagree) to 7 (very strongly agree). Total scores range from 12 to 84, with higher scores being better and indicating an increased perception of social support.
Time frame: Baseline, 3 months (during APP ), and 8 months (after the APP program)
The Short Form 12-Quality of Life (SF12)
The SF12 evaluates the level of activity and perceived physical and mental quality of life. The SF-12 uses a standardized system with scores ranging from 0 to 100, where the general population's average is 50, with higher scores indicating better health. Because it measures relative deviation, the numbers represent the following health levels: Above 50: Better than average health. Exactly 50: Average health status. 40 to 50: Below average health (mild disability or impairment). 30 to 40: Moderate disability or impairment. Below 40: Severe impairment or disability.
Time frame: Baseline, 3 months (during APP ), and 8 months (after the APP program)
The Impact on Participation and Autonomy Questionnaire (IPAQ).
The Impact on Participation and Autonomy (IPA) instrument will be used to assess the patient's self-perceived freedom and social involvement. Individual items are graded on a 0-4 scale. Subscale scores will be calculated for Autonomy Indoors (0-28), Autonomy Outdoors (0-20), Family Role (0-28), Social Relations (0-28), and Work/Education (0-24). Higher subscale totals directly reflect an increase in perceived limitations and restrictions of participation. A reduction in subscale values indicates a positive clinical response to treatment.
Time frame: Baseline, 3 months (during intervention), and 8 months (post-intervention)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Sep 2029, 37 months after the start.
Of 1,293 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 37 months is above that.
Counting every sponsor, half of 1,369 studies reached it within 25 months; a quarter within 12 and three quarters within 44.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Aug 2026, on Nov 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.